ABSTRACT
Objective: Objective of study was assessment of fibrinogen and albumin levels association with orthopedics traumatic patients' outcome who received massive transfusion
Study Design: Observational / cross sectional study
Place and Duration of Study: This study was carried out at orthopedic department of a tertiary care Hospital, Peshawar from March 2014 to July 2015
Materials and Methods: In all patients, the initial resuscitation was performed as soon as admitted to the emergency room. Blood samples were obtained at admission and after 24 h. Part of the serum was frozen and stored at -70°C for determination of fibrinogen and albumin by an immunoturbidometric assay. Electrolytes, hemoglobin, and hematocrit levels were measured on admission. For early restoration, normal saline or ringer was used, clinical events were recorded thereafter until death or hospital discharge
Result: We were studied forty six traumatic patients with severe limb injuries and result showed that 20 patient [41.3%] and 27 [58.7%] were alive
There was significant difference outcome observed in fibrinogen level after 24 h and in case of albumin levels, there was no significant difference observed
Conclusions: When orthopedics traumatic patients received massive transfusion, fibrinogen level play significant role in determination of these patients, while serum albumin is not important factor
ABSTRACT
This study was aimed at reviewing operative and nonoperative treatment of Glenoid fossa fractures in our hospital and view to identifying measures necessary to improve outcome. Retrospective study. This study was conducted at Orthopedic Department of Lady Reading Hospital, Peshawar from March 2012 to July 2014. 21 patients of glenoid fossa fractures were included in this series with 14 males and 7 females. Patients with displacement of >5 mm who were fit to undergo surgery within 3 weeks of injury were operated using a posterior Judet's approach. Overall 8 patients with displaced fractures were operated [Group A] while 9 patients with displaced fractures [Group B] and 4 patients with undisplaced fractures [Group C] were managed nonoperatively. The incidence of associated injuries was 57.14%. The mean length of hospital stay was 15.3, 32.5, and 3.9 days in groups A, B, and C, respectively. In group A, average constant score was 86.98. The least constant score was observed for group B [57.97] while group C had an average constant score of 85.9. Brachial plexus injury and fracture-dislocations had poorer outcome. Operative treatment for displaced glenoid fractures is a viable option at centers equipped to handle critically ill patients and subset of patients with fracture-dislocation as opposed to fracture alone should always be treated operatively due to persistent loss of function
Subject(s)
Female , Male , Humans , Scapula , Treatment Outcome , Tertiary Care Centers , Retrospective Studies , Fractures, BoneABSTRACT
Objective: The objective of our study was to identify the possible risk factors for renal dysfunction after total hip joint replacement surgery
Study Design:Observational cohort study
Place and Duration of Study: This study was conducted in Orthopedic Department of Lady Reading Hospital, Peshawar from March 2013 to February 2014
Materials and Methods: A study was conducted among 212 consecutive primary hip joint replacements performed. According to the RIFLE criteria, increased postoperative serum creatinine was considered indicative ofpostoperative renalinjury
Results: Eighty-one patients [14.1 %] had significant moderate or severe postoperative renal dysfunction in which4 patients [1.9 %] acquired severe and permanent renalimpairment
Conclusion: We identified advanced age, hypertension, general anesthesia, high ASA scores, low intra-operative systolic BP, and prophylactic dicloxacillin as significant risk factors. Smoking, diabetes mellitus, high BMI, gender, and duration of surgery were not identified as significant risk factors
ABSTRACT
The objective of this double-blind, comparative study evaluating efficacy and biochemical effects of optimized Valsartan 80mg [F-3] as monotherapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from January 2011 to September 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive once Valsartan [F-3] daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. The patients treated with optimized Valsartan 80mg [F-3] alone, blood pressure reduction was lower, although significant; reaching values of 140.9 +/- 11.3 / m88.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment. . No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Valsartan 80mg [F-3] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
Objective: This study was aimed at reviewing internal fixation in our hospital and attendant complications with a view to identifying measures necessary to improve outcome. Study Design: Retrospective study Place and Duration of Study: This study was conducted at orthopedic department of Lady Reading Hospital, Peshawar from March 20 12to February 20 14. Materials and Methods: The operation register was used to identify patients who had undergone internal fixation in the main theatre of the hospital over a Three-year period were collected and their case notes were subsequently retrieved from the medical records unit of the hospital. Data pertinent to study interests were extracted using a questionnaire Results: One hundred and fifteen patients had intemal fixation during the study period but case notes of only 100 patients could be retrieved. Most patients were males with male to female ratio of 2.3:l. The mean age of patients was 32.87 and 15.2 years and the mean duration of surgery was 20.56 hours. Plate and screws constituted the most commonly used implants. Interval between surgery and fracture union was increased by long operation time [> 2. lhrs] and occurrence of post operative complications. Conclusion: Improvement in operating facilities and choice of implants would reduce operation time and post operative complications thereby impacting positively on fracture union time
ABSTRACT
The objective of this double-blind, comparative study evaluating efficacy and biochemical effects of optimized felodipine 10mg [F-7] as monotherapy with comparison to placebo in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from March 2011 to October 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive once Felodipine [F-7] daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. The patients treated with optimized Felodipine 10mg [F-7] alone, blood pressure reduction was lower, although significant; reaching values of 140.2 +/- 11.3 /87.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment. No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Felodipine 10mg [F-7] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
The objective of this double-blind, Placebo control study evaluating efficacy and biochemical effects of optimized Atenolol 50mg [F-9] as monotherapy in adult patient with essential hypertension. Double-blind, Placebo control study. This study was conducted at the Department of Biochemistry, University of Karachi from February 2011 to September 2011. This was multicenter randomized, double-blind, Placebo control study. Patients were randomized to receive once Atenolol [F-9] daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. The patients treated with optimized Atenolol 50mg [F-9] alone, blood pressure reduction was lower, although significant; reaching values of 140.9 +/- 11.31 m88.9 + 5.5 mmHg [p <0.05 versus Placebo] by the end of eight weeks of treatment. No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with anti hypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Atenolol50mg [F-9] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. It suppresses the effects of angitensin II at its receptors, thereby blocking the rennin-angiotensin system. The rennin-angiotensin system plays a crucial role in the control of blood pressure, and in particular it is felt to play crucial role in hypertension. The objective of this double-blind, comparative study evaluating efficacy and biochemical effects of optimized Losartan Potassium 50mg [F-6] as monotherapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from January 2010 to August 2010. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive once Losartan Potassium 50mg [F-6] daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. The patients treated with optimized Losartan potassium [F-6] alone, blood pressure reduction was lower, although significant; reaching values of 140.9 +/- 11.3 / m88.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment.. No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Losartan potassium [F-6] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. Amlodipine is a calcium channel-blocking agent with vasodilator activity and Ramipril is ACE inhibitor. The objective of this double-blind, comparative study evaluating the efficacy of Amlodpine 5 mg and Ramipril 1.25 mg in combination and as mono therapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted in the department of Biochemistry, University of Karachi from February 2011 to July 2011. This was multicenter randomized, double-blind, comparative study. Patients were selected from different hospitals of Orangi Town Karachi from February 2011 to July 2011 and study was conducted in the department of Biochemistry, University of Karachi. Patients were randomized to receive Amlodopine [5 mg] once daily Ramipril [1.25 mg] once daily for 8 weeks. The analysis of antihypertensive efficacy and biochemical effects of a therapeutic regimen in the long term becomes important .In study patents were randomized to receive amlodipine 5 mg once daily, Ramipril 1.25 mg once daily, the combination of amlodipine 5 mg with Ramipril 1.25 mg once daily. In the patients treated with combination of Amlodipine 5mg and Ramipril 1.25 mg tablets blood pressure reduction was significantly lower, reaching values of 130.4 +/- 10.2 / 84.1 +/- 7.4 mmHg by the end of eight weeks of treatment. The results of this study demonstrated that the combination of amlodipine 5 mg with Ramipril 1.25 mg once daily has a high antihypertensive efficacy and showed synergetic effect
Subject(s)
Humans , Female , Male , Hypertension/therapy , Amlodipine , Ramipril , Drug Therapy, Combination , Blood Pressure , Double-Blind MethodABSTRACT
Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. ACE inhibitors or angiotensin converting enzyme inhibitors reduce peripheral vascular resistance via blockage of the angiotensin converting enzyme. This action reduces the myocardial oxygen consumption. This study aimed to evaluate the efficacy of once-daily optimized Ramipril 1.25 mg [F-4] versus placebo. Placebo-controlled, comparative study. This study was conducted in the department of Biochemistry, University of Karachi from January 2010 to June 2010. This was multicenter, randomized, placebo-controlled, comparative study. Patients were selected from different hospitals of Orangi Town Karachi and study was conducted in the department of Biochemistry, University of Karachi. Patients were randomized to receive optimized Ramipril 1.25 mg [F-4] once daily and Placebo once daily for 8 weeks. The efficacy variable was change from baseline at the end of study which was evaluated. The patients treated with optimized Ramipril 1.25 mg tablet [F-4] alone, blood pressure reduction was lower, although significant; reaching values of 139.9 +/- 11.3 / 89.9 +/- 5.5 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment. The results of this study demonstrated that the optimized Ramipril 1.25 mg [F-4] has a high antihypertensive efficacy and achieve desired blood pressure for eight weeks
Subject(s)
Humans , Female , Male , Hypertension/therapy , Antihypertensive Agents , Ramipril , Blood PressureABSTRACT
An adequate blood pressure is a treatment of hypertension and it is the risk of cardiovascular morbidity and mortality so proper therapy is essential. Combination therapy of amlodipine plus atorvastatin improved vascular compliance, an indicator of structural and functional vascular changes, and the beneficial effect on small arteries appeared to be more than additive. This study aimed to evaluate the efficacy and biochemical effects of once-daily optimized Amlodpine/Atorvastatin 5/10 mg [F-6] versus placebo. placebo-controlled, comparative study. This study conducted in the Department of Biochemistry, University of Karachi from July 2010 to January 2011. This was multicenter, randomized, placebo-controlled, comparative study. Patients were selected from different hospitals of Orangi Town Karachi and samples were analyzed in the department of Biochemistry, University of Karachi. Patients were randomized to receive optimized Amlodpine/Atorvastatin 5/10 mg [F-6] once daily and Placebo once daily for 8 weeks. The efficacy and biochemical effects variables were change from baseline at the end of study which was evaluated. In the patients treated with optimized Amlodipine /Atorvastatin 5/10mg tablets' [F-6] alone, blood pressure reduction was lower, although significant, reaching values of 136.9 +/- 10.7 / 88.2 +/- 6.3 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment. Thus, the drug regimens used may be considered neutral as regards glucose and significantly reduce LDL-Cholesterol. Due to the high antihypertensive efficacy and hypolipidemic and no biochemical effects of the optimized Amlodipine/Atorvastatin 5/10 mg [F-6] it is an excellent option for the treatment of hypertension and hyperlipidemia patients, with a high potential to reduce cardiovascular risks
ABSTRACT
Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. Angiotensin converting enzyme inhibitors have been shown to block the activation of the renin-angiotensin system in the plasma as well as in the vascular wall. The objective of this double-blind, comparative study evaluating the biochemical effects of optimized Ramipril 1.25 mg tablet as monotherapy in adult patient with essential hypertension. Double-blind, comparative study. This study was conducted at the Department of Biochemistry, University of Karachi from January 2011 to August 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive Ramipril [1.25 mg] once daily for 8 weeks and at the end of study biochemical evaluation was done. In the patients treated with optimized Ramipril 1.25 mg tablets showed antihypertensive property. No significant variations of blood glucose and different parameters of lipid profile were observed during the eight weeks of treatment. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Ramipril 1.25 mg [F-4] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks
ABSTRACT
The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. Amlodipine is a calcium channel-blocking agent with vasodilator activity and Ramipril is ACE inhibitor. The objective of this double-blind, comparative study evaluating the biochemical effects of Amlodipine 5 mg and Ramipril 1.25 mg in combination and as monotherapy in adult patient with essential hypertension, double-blind, comparative study. This study was conducted at the department of Biochemistry, University of Karachi from December 2010 to September 2011. This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive Amlodopine [5 mg] once daily, Ramipril [1.25 mg] once daily and combination of amlodipine 5 mg with Ramipril 1.25 mg once daily for 8 weeks and at the end of study biochemical evaluation was done. In the patients treated with combination of Amlodipine 5 mg and Ramipril 1.25 mg tablets showed synergetic effect and no significant biochemical effects. We can suggest that good tolerability and no biochemical and hematological effects of combination of Amlodipine 5 mg and Ramipril 1.25 mg to formulate in a single dosage forms [tablet] because it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks